Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: Ultradian secretory pulsatility and diurnal variation

Neurobiology of Aging

Volumn 18, Issue 3, 1997, Pages 285-289

  Hartmann, A ^a   Veldhuis, J D ^b   Deuschle, M ^a   Standhardt, H ^a   Heuser, I ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b NATIONAL SCIENCE FOUNDATION   (United States)

Author keywords

24 Hour secretory pattern; Alzheimer's disease; Cortisol; Deconvolution analysis; Parkinson's disease

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PULSATILE FLOW; SECRETORY GRANULE; ULTRADIAN RHYTHM;

EID: 0030739052     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(97)80309-0     Document Type: Article

References (45)

1. Airaghi L., Catania A., Gramigna C., Manfredi M. G., Franceschi M., Zanussi C. Resistance of beta-endorphin to dexamethasone inhibition in Parkinson's and Alzheimer's disease. Int. J. Neurosci. 56:1991;73-76.
2. Asnis G. M., Halbreich U., Ryan N. D., Rabinowicz H., Puig-Antich J., Nelson B., Novacenko H., Friedman J. H. The relationship of the dexamethasone suppression test (1 and 2 mg) to basal plasma cortisol levels in endogenous depression. Psychoneuroendocrinology. 12:1987;295-301.
3. Davis K. L., Davis B. M., Greenwald B. S., Mohs R. C., Mathé A. A., Johns C. A., Horvath T. B. Cortisol and Alzheimer's disease, I: Basal studies. Am. J. Psychiatry. 143:1986;300-305.
4. De Kloet E. R. Brain corticosteroid receptor balance and homeostatic control. Front. Neuroendocrinol. 12:1991;95-164.
5. De Leon M. J., McRae M., Tsai J. R., George A. E., Marcus D. L., Freedman M. L., Wolf A. P., McEwen B. E. Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy. Lancet. ii:1988;391-392.
6. Deuschle M., Schweiger U., Weber B., Gotthardt U., Körner A., Schmider J., Standhardt H., Lammers C. H., Heuser I. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. Clin. Endocrinol. Metab. 82:1997;234-238.
7. Diehl D. J., Gershon S. The role of dopamine in mood disorders. Comp. Psychiatry. 33:1992;115-120.
8. Folstein M. F., Folstein S. E., Mc Hugh P. R. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
9. Francheschi M., Airaghi L., Gramigna C., Truci G., Manfredi M. G., Canal N., Catania A. ACTH and cortisol secretion in patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 54:1991;836-837.
10. Gottfries C. G., Balldin J., Blennow K., Bråne G., Karlsson I., Regland B., Wallin A. Regulation of the hypothalamic-pituitary-adrenal axis in dementia disorders. Ann. NY Acad. Sci. 746:1994;336-343.
11. Gurevitch D., Siegel B., Dumlao M., Perl E., Chaitin P., Bagne C., Oxenkrug G. HPA axis responsitivity to dexamethasone and cognitive impairment in dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 14:1990;297-308.
12. Halbreich U., Asnis G. M., Shindldecker R., Zumoff B., Nathan S. Cortisol secretion in endogenous depression. I: basal plasma levels. Arch. Gen. Psychiatry. 42:1985;904-908.
13. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
14. Hantz P., Caradoc-Davies G., Caradoc-Davies T., Weatherall M., Dixon G. Depression in Parkinson's disease. Am. J. Psychiatry. 151:1994;1010-1014.
15. Hatzinger M., Z'Brun A., Hemmeter U., Seifritz E., Baumann F., Holsboer-Trachsler E., Heuser I. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol. Aging. 16:1995;205-209.
16. Hoehn M. M., Yahr M. D. Parkinsonism: Onset, progression and mortality. Neurology. 17:1967;427-442.
17. Holsboer F. Neuroendocrinology of mood disorders. Bloom F. E., Kupfer D. J. Psychopharmacology: The fourth generation of progress. 1995;957-969 Raven Press, New York.
18. Jonsson G. Chemical neurotoxins as denervation tools in neuroscience. Annu. Rev. Neurosci. 3:1980;169-187.
19. Kawamura T., Kinoshita M., Iwasaki Y., Nemoto H. Low-dose dexamethasone suppression test in Japanese patients with Parkinson's disease. J. Neurol. 234:1987;264-265.
20. Kostic V. S., Covickovic-Sternic N., Beslac-Bumbasirevic L., Ocic G., Pavlovic D., Nikolic M. Dexamethasone suppression test in patients with Parkinson's disease. Mov. Disord. 5:1990;23-26.
21. Linkowski P., Mendlewicz J., Le Clerq R., Brasseur M., Hubain P., Goldstein J., Copinschi G., Van Cauter E. The 24-hour profile of ACTH and cortisol in major depressive illness. J. Clin. Endocrinol. Metab. 61:1985;429-438.
22. McEwen B. E. Re-examination of the glucocorticoid hypothesis of stress and aging. Prog. Brain Res. 33:1992;365-383.
23. Miller A. H., Sastry G., Speranza A. J., Lawlor B., Mohs R. C., Ryan T. M., Gabriel S. M., Serby M., Schmeidler J., Davis K. L. Lack of association between cortisol hypersecretion and nonsuppression on the DST in patients with Alzheimer's disease. Am. J. Psychiatry. 151:1994;267-270.
24. Mizobuchi M., Hineno T., Kakimoto Y., Hiratani K. Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP)-treated dogs. Brain Res. 612:1993;319-321.
25. Molchan S. E., Hill J. L., Mellow A. M., Lawlor B. A., Martinez R., Sunderland T. The dexamethasone suppression test in Alzheimer's disease and major depression: Relationship to dementia severity, depression, and CSF monoamines. Int. Psychogeriat. 2:1990;99-122.
26. Näsman B., Olsson T., Seckl J. R., Eriksson S., Vitanen M., Bucht G., Carlstrom K. Abnormalities in adrenal androgens, but not of glucocorticoids, in early Alzheimer's disease. Psychoneuroendocrinology. 20:1995;83-94.
27. O'Brien J., Ames D., Schweitzer I. HPA axis function in depression and dementia: A review. Int. J. Geriatr. Psychiatry. 8:1993;887-898.
28. Pfeiffer R. F., Hsieh H. H., Diercks M. J., Glaeske C., Jefferson A., Cheng S. C. Dexamethasone suppression test in Pakinson's disease. Yahr M. D., Bergmann K. J. Parkinson's disease. Advances in neurology. 45:1986;439-442 Raven Press, New York.
29. Pfohl B., Sherman B., Schlechte J., Stone R. Pituitary-adrenal rhythm disturbances in psychiatric depression. Arch. Gen. Psychiatry. 42:1985;897-903.
30. Rabey J. M., Scharf M., Oberman Z., Zohar M., Graff E. Cortisol, ACTH, and beta-endorphin after dexamethasone administration in Parkinson's dementia. Biol. Psychiatry. 27:1990;581-591.
31. Raskind M., Peskind M., Rivard M. F., Veith R., Barnes R. Dexamethasone suppression test and cortisol circadian rhythm in primary degenerative dementia. Am. J. Psychiatry. 139:1982;1468-1471.
32. Ratka A., Sutanto W., Bloemers M., De Kloet E. R. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology. 50:1989;117-123.
33. Schweiger U., Deuschle M., Körner A., Lammers C. H., Schmider J., Gotthardt U., Holsboer F., Heuser I. Low lumbar bone mineral density in patients with major depression. Am. J. Psychiatry. 151:1994;1691-1693.
34. Seckl J. R., Dickson K. L., Yates C., Fink G. Distribution of glucocorticoid and mineralocorticoid receptor messenger mRNA expression in human postmortem hippocampus. Brain Res. 561:1991;332-337.
35. Seckl J. R., French K. L., O'Donnell D., Meaney M. J., Nair N. P. V., Yates C., Fink G. Glucocorticoid receptor gene expression is unaltered in hippocampal neurons in Alzheimer's disease. Mol. Brain Res. 18:1994;239-245.
36. Sharma R., Marka H. R. Mortality in affective disorders. J. Affect. Disord. 31:1994;91-96.
37. Skare S., Pew B., Dysken M. The dexamethasone suppression test in dementia: A review of the literature. J. Geriatr. Pschiatr. Neurol. 3:1990;124-138.
38. Veldhuis J. D., Carlson M. L., Johnson M. L. The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc. Natl. Acad. Sci. USA. 84:1987;7686-7690.
39. Veldhuis J. D., Johnson M. L. Deconvolution analysis of hormone data. Methods Enzymol. 210:1992;539-575.
40. Verney C., Baulac M., Berger M., Alvarez C., Vigny A., Helle K. B. Morphologic evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rats. Neuroscience. 14:1985;1039-1052.
41. Weiner M. F., Edland S. D., Luszczynska H. Prevalence and incidence of Major depression in Alzheimer's disease. Am. J. Psychiatry. 151:1994;1006-1009.
42. Weiner M. F., Vobach S., Svetlik D., Risser R. C. Cortisol secretion and Alzheimer's disease progression: A preliminary report. Biol. Psychiatry. 34:1993;158-161.
43. Wolkowitz O. M. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology. 19:1994;233-255.
44. Yau J. L. W., Seckl J. R. Central 6-hydroxydopamine lesions decrease mineralocorticoid, but not glucocorticoid receptor gene expression in the rat hippocampus. Neurosci. Lett. 142:1992;159-162.
45. Yau J. L. W., Dow R. C., Rink G., Seckl J. R. Medial septal cholinergic lesions increase mineralocorticoid and glucocorticoid receptor mRNA expression. Brain Res. 577:1992;155-160.